HER2 positive breast cancer

• HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc … Not authorised
  2024-516253-49-00 4 "advanced/metastatic HER2-positive breast carcinoma"
• Evaluation of a new radiotracker for predicting complete response after neoadjuvant chemotherapy in HER2-positive early breast cancer Pending
  2025-523286-23-00 9 "Breast Cancer"
• PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR … Pending
  2025-524613-89-00 9 "HER2 positive advanced breast cancer"
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 "Pretreated Unresectable Locally Advanced or Metastatic human"
• HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc … Recruiting
  2024-516253-49-01 4 2025-12-12 "advanced/metastatic HER2-positive breast carcinoma"
• A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting
  2023-507555-29-00 9 2024-08-16 "LA/mGC/GEJC (locally advanced unresectable or metastatic gas"
• SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patient … Recruiting
  2024-516173-76-01 5 2025-04-22 "HER2-positive or HER2-low (incl. ultra-low) early breast can"
• A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast c … Recruiting
  2024-516333-12-00 1 2024-12-16 "HER2 positive patients under HER2 maintenance therapy (metas"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 "Advanced or metastatic solid tumors including hormone recept"
• Basket study for oligo-metastatic breast cancer - ANISE Recruiting
  2023-505039-11-00 4 2024-05-02 "breast cancer, HER2-positive, oligometastatic disease"
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 "breast cancer"
• A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting
  2023-506330-73-00 5 2024-03-13 "Advanced (unresectable or metastatic) human epidermal growth"
• DS-1103a Combination Therapy First-in-human (FIH) Study Recruiting
  2023-503965-48-00 1 2024-01-11 "Advanced (unresectable or metastatic) human epidermal growth"
• Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 study Recruiting
  2024-518192-61-00 9 2023-12-08 "Breast cancer"
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 4 2023-06-23 "Non-metastatic HER2-positive Breast Cancer"
• TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIV … Recruiting
  2023-509321-50-00 5 2021-04-15 "HER2-POSITIVE EARLY BREAST CANCER"
• An Extension Study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients pr … Recruiting
  2023-503479-79-00 4 2011-06-17 "Metastatic Cancer"
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Recruitment ended
  2023-509716-29-00 9 2024-09-23 "Solid Tumors, Colorectal Cancer and Breast Cancer"
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Recruitment ended
  2024-514458-61-01 4 2024-02-05 "HER2+ early breast cancer"
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Recruitment ended
  2024-514630-21-00 4 2022-08-11 "HER2 positive (HER2+), Hormone Receptor positive (HR+) Early"
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Recruitment ended
  2022-500014-26-00 5 2022-06-24 "Locally-Advanced unresectable or Metastatic breast cancer (M"
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Recruitment ended
  2023-503826-37-00 5 2022-02-11 "Unresectable locally-advanced or metastatic HER2+ breast can"
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Recruitment ended
  2023-508738-32-00 4 2021-06-16 "Previously untreated and histologically confirmed HER2-Posit"
• A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr … Recruitment ended
  2024-510588-53-00 11 2021-06-10 "Treatment of patients with HER2-positive breast cancer with "

Showing 1–24 of 40 trials